SUPERNUS PHARMACEUTICALS, INC. (SUPN) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-03-18

SUPERNUS PHARMACEUTICALS, INC. (SUPN) — no SEC Form 4 insider filings recorded in the last 90 days. 4 Form 8-K material event filings were reported by SUPN in the last 90 days. InsiderAlpha tracks every SUPN SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About SUPERNUS PHARMACEUTICALS, INC. (SUPN)

SIC classification	Pharmaceutical Preparations (SIC 2834)
SEC CIK	0001356576

90-Day SEC Filing Activity

Form 8-K filings (90d)	4
Latest Form 4 filing	2026-03-18

Recent SUPN Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-03-18	Bhatt Padmanabh P.	Sr. VP of IP, CSO	M — Option exercise [10b5-1]	7.2K	$39.40	$286K	SEC
2026-03-18	Bhatt Padmanabh P.	Sr. VP of IP, CSO	S — Open-market sale [10b5-1]	6.8K	$49.55	$339K	SEC
2026-03-18	Bhatt Padmanabh P.	Sr. VP of IP, CSO	S — Open-market sale [10b5-1]	412	$50.48	$21K	SEC
2026-03-17	Bhatt Padmanabh P.	Sr. VP of IP, CSO	M — Option exercise [10b5-1]	15.0K	$38.60	$579K	SEC
2026-03-17	Bhatt Padmanabh P.	Sr. VP of IP, CSO	S — Open-market sale [10b5-1]	27.7K	$49.95	$1.38M	SEC
2026-03-17	Bhatt Padmanabh P.	Sr. VP of IP, CSO	S — Open-market sale [10b5-1]	22.3K	$50.73	$1.13M	SEC
2026-03-17	Bhatt Padmanabh P.	Sr. VP of IP, CSO	M — Option exercise [10b5-1]	22.8K	$39.40	$896K	SEC
2026-03-17	Bhatt Padmanabh P.	Sr. VP of IP, CSO	M — Option exercise [10b5-1]	12.2K	$36.75	$450K	SEC
2026-03-16	Bhatt Padmanabh P.	Sr. VP of IP, CSO	M — Option exercise [10b5-1]	5.0K	$27.94	$140K	SEC
2026-03-16	Bhatt Padmanabh P.	Sr. VP of IP, CSO	M — Option exercise [10b5-1]	22.8K	$36.75	$836K	SEC
2026-03-16	Bhatt Padmanabh P.	Sr. VP of IP, CSO	S — Open-market sale [10b5-1]	34.1K	$50.18	$1.71M	SEC
2026-03-16	Bhatt Padmanabh P.	Sr. VP of IP, CSO	S — Open-market sale [10b5-1]	15.9K	$50.49	$802K	SEC
2026-03-16	Bhatt Padmanabh P.	Sr. VP of IP, CSO	M — Option exercise [10b5-1]	4.2K	$29.61	$126K	SEC
2026-03-16	Bhatt Padmanabh P.	Sr. VP of IP, CSO	M — Option exercise [10b5-1]	18.0K	$32.20	$580K	SEC
2026-03-13	Khattar Jack A.	President, CEO	S — Open-market sale [10b5-1]	120	$51.75	$6K	SEC

All transactions sourced from SEC EDGAR Form 4 filings for SUPERNUS PHARMACEUTICALS, INC. (SUPN). Updated in real time as new filings are submitted to the SEC.

Recent SUPN Form 8-K Material Events

2026-06-18 — Item 5.07, 9.01 [SEC]
2026-05-20 — Item 2.03, 9.01 [SEC]
2026-05-05 — Item 2.02, 9.01 [SEC]
2026-04-22 — Item 2.02 · Earnings · neutral [SEC]
Supernus Pharmaceuticals announced that it will report Q1 2026 financial results on May 5, 2026 after market close, with a conference call at 4:30 p.m. ET. This is a routine earnings announcement notification with no forward guidance or performance indicators disclosed.
2026-04-07 — Item 1.01, 2.01, 9.01 · Acquisition · positive [SEC]
Supernus Pharmaceuticals entered into a definitive Asset Purchase Agreement on April 1, 2026 to acquire all rights to NV-5138 (SPN-820), a pharmaceutical compound, from Navitor Pharmaceuticals. The purchase price consists of Supernus completing a Phase 2b study and making milesto

Recent Insider Filings

2026-03-18 — Bhatt Padmanabh P. (Sr. VP of IP, CSO)
2026-03-16 — Khattar Jack A. (President, CEO)
2026-03-16 — Hudson Frederick M. (Director)
2026-03-10 — Khattar Jack A. (President, CEO)
2026-03-10 — Mottola Frank (SVP, Chief Tech. Ops. Officer)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in SUPN insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

SUPN Insider Trading — FAQ

What is the latest insider trade for SUPN?: SUPERNUS PHARMACEUTICALS, INC. (SUPN) had 0 insider filings in the last 90 days, with the most recent on 2026-03-18. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying SUPN stock?: 0 insider purchases of SUPN were filed in the last 90 days.
How many insiders are selling SUPN stock?: 0 insider sales of SUPN were filed in the last 90 days.
Where can I see SUPN SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every SUPN SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Related Companies — Recent Insider Activity

Learn More

Open the live SUPN dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.